T2 Biosystems, Inc. · OTC:TTOO
T2 Biosystems — Investor Day (April 2022)
28 slides from T2 Biosystems's investor day presentation, Apr 12, 2022
Slide 1: Analyst and Investor Day
Exhibit 99.1 Analyst and Investor Day (NASDAQ: TTOO) April 12, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ( we , us , our , T2 , T2 Biosystems or the Company ) and include those about T2's goals, strategies, plans, objectives, prospects,
Slide 3: Agenda
Agenda Company Overview – 5 min. John Sperzel, Chairman and CEO Panel Discussion: Culture-Independent Diagnostics – 30 min. Aparna Ahuja, MD, Chief Medical Officer James Snyder, PhD, DABMM, FAAM Thomas Walsh, MD, PhD Commercial Strategy – 10 min. Brett Giffin, Chief Commercial Officer Product Pipeli
Slide 4: Company Overview
Company Overview John Sperzel, Chairman and CEO © 2022 T2 Biosystems. All Rights Reserved. 4
Slide 5: Our mission is to change the way medicine is practiced
Our mission is to fundamentally change the way medicine is practiced through transformative culture-independent diagnostics that improve the lives of patients around the world © 2022 T2 Biosystems. All Rights Reserved. 5
Slide 6: Investment Highlights
Investment Highlights Proprietary Platform Novel Diagnostics Large Market Opportunity Innovative proprietary Direct from blood ID Initial target market technology platform in 3-5 hours $2 billion+ (magnetic resonance) (culture independent) Established Reimbursement Robust Product Pipeline Commercial
Slide 7: Significant Economic and Human Toll from Sepsis
Significant Economic and Human Toll from Sepsis Sepsis is the leading cost, cause of death, and cause of readmission in U.S. hospitals • Sepsis is the #1 cost of U.S. hospitalization 1 ($62 billion annually) • Sepsis is the #1 cause of death in U.S. hospitals 2 (270,000 deaths annually) • Sepsis is
Slide 8: 2022 Corporate Priorities
2022 Corporate Priorities ACCELERATE SALES ENHANCE OPERATIONS ADVANCE PIPELINE © 2022 T2 Biosystems. All Rights Reserved. 8
Slide 9: Panel Discussion
Panel Discussion Aparna Ahuja, MD, Chief Medical Officer James Snyder, Ph.D., DABMM, FAAM Tom Walsh, MD, Ph.D. © 2022 T2 Biosystems. All Rights Reserved. 9
Slide 10: Sepsis Represents $62 Billion in U.S. Healthcare Costs
Sepsis Represents $62 Billion in U.S. Healthcare Costs 2,3 Claims more U.S. lives each year than the top three cancers combined: lung, colorectal, breast Costs the U.S. Causes the death of Claims more lives each healthcare system nearly 270,000 year than the three top 1 2 $62 billion annually Americ
Slide 11: The Challenge of Detecting Sepsis-Causing Pathogens
The Challenge of Detecting Sepsis-Causing Pathogens The current standard is a race against time, relying on empiric probability-based protocols HOUR HOUR HOUR HOUR 0 24 48 72+ Empiric Protocol is only optimal in 30-60% of cases Broad Spectrum Antibiotics Each hour of delayed treatment increases mort
Slide 12: Rapid Detection of Sepsis-Causing Pathogens is Critical
Rapid Detection of Sepsis-Causing Pathogens is Critical T2 Biosystems provides species and resistance gene identification directly from whole blood within 3-5 hours of the first blood draw, often before the second dose of broad-spectrum antibiotics is delivered, enabling clinicians to achieve target
Slide 13: Novel Culture-Independent BSI and AMR Diagnostics
Novel Culture-Independent BSI and AMR Diagnostics Fully-automated T2Dx Instrument, Sepsis Test Panels and SARS-CoV-2 Panel Rapid: Results in 3-5 hours 1 2 3 4 Sensitivity: 91% Sensitivity: 90% Sensitivity: ≥ 99% PPA: 95% 2 3 4 1 2 Specificity: 98% Specificity: ≥ 99% NPA: 100% Easy-to-use: Specificit
Slide 14: Meta-analysis of Controlled Studies (Peer-Reviewed)
Meta-analysis of 14 Controlled Studies (Peer-Reviewed) Highlights benefits of T2 Biosystems sepsis technology vs. blood culture Title: Antimicrobial and Resource Utilization with T2 Magnetic Resonance for Rapid Diagnosis of Bloodstream Infections: Systematic Review with Meta-analysis of Controlled S
Slide 15: Panel Discussion: Culture-Independent Diagnostics
Panel Discussion: Culture-Independent Diagnostics © 2022 T2 Biosystems. All Rights Reserved. 15
Slide 16: Commercial Strategy
Commercial Strategy Brett Giffin, Chief Commercial Officer © 2022 T2 Biosystems. All Rights Reserved. 16
Slide 17: Commercial Strategy
Commercial Strategy Increase instrument installed base and expand sepsis testing UNITED STATES MARKET INTERNATIONAL MARKET - Installed base: 90 T2Dx Instruments - Installed base: 55 T2Dx Instruments - Sales force expansion - Sales force expansion - Enhanced training programs - Geographic expansion (
Slide 18: Growing Independent Support for T2 Technology
Growing Independent Support for T2 Technology Included in dozens of independent, real-world clinical case studies demonstrating clinical utility of T2Bacteria and T2Candida (www.t2biosystems.com) TM U.S. Food & Drug Administration granted breakthrough device designation for T2Resistance Panel ® U.S.
Slide 19: Implementation Strategy
Implementation Strategy Execution - Sales, Medical Affairs, Service Education Implementation Identify Use Cases Routine Testing Clinical and economic value Patient selection criteria: Secure approval for go-live and Establish patient sample and incorporation into sepsis protocol proposition Hematolo
Slide 20: Product Pipeline
Product Pipeline Roger Smith, Senior VP Science R&D © 2022 T2 Biosystems. All Rights Reserved. 20
Slide 21: T2 Biosystems' Product Pipeline
T2 Biosystems’ Product Pipeline Product Name Collaborator Phase I Phase II Phase III Phase IV Phase V (Feasibility) (Development) (Verification) (Clinical/Regulatory) (Commercial Launch) Initiated U.S. Trial ® Launched (EU) - CE mark T2Resistance Panel BARDA (Q4 2021) Initiated U.S. Trial ® T2Biothr
Slide 22: T2Resistance Panel
® T2Resistance Panel The first direct-from-blood detection of antibiotic resistance markers • Detection of 13 antibiotic resistance genes from • Covers the most clinically important antibiotic both Gram-positive and Gram-negative pathogens resistance pathogens direct-from-blood, without the wait for
Slide 23: T2Biothreat Panel
® T2Biothreat Panel Novel direct-from-blood detection of biothreat pathogens 1 • Simultaneously detects 6 biothreat pathogens direct-from-blood, without the wait for blood culture • Proposed to be an aid in the diagnosis of anthrax, tularemia, melioidosis, glanders, typhus fever and plague • Bioterr
Slide 24: Comprehensive Panel BSI and AMR
Comprehensive Panel Bloodstream Infections (BSI) and Antimicrobial Resistance (AMR) • Direct-from-blood test panel with results in approximately 3 hours • Detects a combination of genus, complex, species and resistance markers • Proposed to detect >95% of blood stream infections from a single blood
Slide 25: Next-Generation Instrument
Next-Generation Instrument Design specifications • Random access, fully-automated system able to process multiple samples simultaneously • Designed in parallel with comprehensive panel for BSI and AMR • Requires no up-front sample processing • Processes whole blood samples • Utilizes a self-containe
Slide 26: Financial Summary
Financial Summary John Sprague, Chief Financial Officer © 2022 T2 Biosystems. All Rights Reserved. 26
Slide 27: Financial Summary
Financial Summary 1 2022 Guidance 2021 2020 % Change 55% Total Revenue $28-31 million $28.1 million $18.1 million 42% Product Revenue $16-17 million $16.6 million $11.7 million 78% R&D Revenue $12-14 million $11.4 million $6.4 million T2Dx Instruments 60-70 32 57 2 Cash Balance $33.8 million 1. Guid
Slide 28: Q&A T2 Biosystems Management Team
Q&A T2 Biosystems Management Team © 2022 T2 Biosystems. All Rights Reserved. 28